Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 10 May 2024, including: AstraZeneca PLC’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer Inc. recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer Bio, Inc. partners up for respiratory therapy.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up" - Scrip, 8 May, 2024.)
(Also see "Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies" - Scrip, 8 May, 2024.)
(Also see "Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy" - Scrip, 6 May, 2024.)
(Also see "China’s First Non-Profit Rare Disease Foundation Pleas For Therapies" - Scrip, 8 May, 2024.)
(Also see "Gossamer Partners With Chiesi To Accelerate Seralutinib Development" - Scrip, 6 May, 2024.)
